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Main Text
Small nuclear RNAs (snRNAs) are among the most abundant and extensively studied RNAs in eukaryotic cells. These uridine (U)-rich non-coding RNAs -which include U1, U2, U4, U5, and U6 -were discovered nearly fifty years ago 1 , and studies of their function lead to the elucidation of the fundamental molecular mechanisms that mediate pre-mRNA splicing [2] [3] [4] [5] .
snRNAs undergo a series of processing events that are required for incorporation into spliceosomes [6] [7] [8] . Except for U6 and U6atac snRNA 9 , snRNAs are synthesized by RNA polymerase II as precursors that initially contain a 3'-end extension and acquire an N 7 -methylguanosine (m 7 G) cap 10 . These snRNAs are exported into the cytosol where they are incorporated into small nuclear ribonucleoproteins (snRNPs) by binding to Sm proteins 11 . Their m 7 G cap is then further methylated to form the N 2,2,7 -trimethylguanosine (TMG) cap and the snRNA 3'-end is trimmed [12] [13] [14] . snRNAs become highly stable as a result of their incorporation into snRNPs and are transported back to the nucleus where they assemble into spliceosomes that mediate pre-mRNA splicing [6] [7] [8] . snRNAs that are not properly processed are not incorporated into snRNPs and are therefore unstable and degraded 15, 16 .
Importantly, snRNAs contain a set of constitutive nucleotide modifications that are highly conserved across species and essential for snRNA integrity and function 17, 18 . Thus, all mature snRNAs are thought to exist as a single molecular species, and deviations outside of this species are not thought to be utilized by spliceosomes.
Here we show that all Sm-class spliceosomal snRNAs can exist as two distinct subtypes, differing by a single methyl modification. The transcription-start nucleotide of most snRNAs is an adenosine with a constitutive 2'-O-methyl modification on the ribose sugar. We find that these adenosines are subjected to a second, reversible methylation selectively at the N 6 -position on the adenine base. This methylation converts the canonical single-methylated m 1 -snRNA to a dimethylated m 2 -snRNA. m 2 -snRNAs are assembled into snRNPs and promote the splicing of exons that are normally poorly included in cells. Furthermore, we find that m 2 -snRNAs are major targets of the RNA demethylase FTO, which is highly selective for demethylating the N 6 -methyl group in m 6 Am. We find that FTO functions early during snRNA biogenesis to convert the m 2 -snRNA to m 1 -snRNA. FTO-mediated demethylation of m 2 -snRNA is blocked by intracellular metabolites, including the oncometabolite 2-hydroxyglutarate, linking metabolism to snRNA methylation state, FTO activity, and splicing. Taken together, these data reveal a methylation switch, controlled by FTO, that results in the formation of a distinct form of snRNAs that may influence transcriptome diversity.
The RNA demethylase FTO selectively demethylates snRNAs
The concept that RNA can undergo reversible methylation was first proposed based on studies of fat mass and obesity-associated protein (FTO) 19 . FTO is a member of the ALKB family of DNA nucleotide repair enzymes, but was found to exhibit weak demethylase activity towards methylated RNA nucleotides such as N 3 -methyluridine (m 3 U) and N 6 -methyladenosine (m 6 A) 19, 20 . We recently showed that FTO shows highly efficient demethylation of N 6 ,2'-Odimethyladenosine (m 6 Am), with nearly 100-fold higher catalytic activity towards m 6 Am compared to m 6 A (ref. 21) . FTO selectively demethylates the N 6 -methyl modification, resulting in 2'-O-methyladenosine (Am) 21 . m 6 Am is exclusively found within the "extended cap" of RNA polymerase II-transcribed RNAs, at the transcription-start nucleotide immediately adjacent to the m 7 G (ref. 22, 23) .
The physiological importance of RNA demethylation was demonstrated by analysis of FTOdeficient mice, which exhibit altered synaptic transmission, metabolic abnormalities, and growth retardation 24, 25 . Additionally, humans with loss-of-function FTO mutations show severe developmental defects and microcephaly 26 . FTO has been proposed to mediate its effects by influencing alternative splicing of mRNA, based on transcriptome-wide splicing alterations detected in FTO-deficient cells 27, 28 .
It remains unclear which methylated residues in the transcriptome are preferentially targeted by FTO. m 6 Am shows high stoichiometry in mRNA, which suggests that FTO does not efficiently demethylate m 6 Am to Am in mRNA 21 . Indeed, nearly all the m 6 Am peaks in mRNA showed increases of less than 10% in Fto knockout brain compared to wild-type 21 . Although FTO clearly demethylates m 6 Am in mRNA, the moderate effect of FTO-mediated mRNA demethylation likely reflects the fact that FTO is nuclear, while mRNAs are predominantly cytosolic 21 . Although FTO can translocate to the cytoplasm and have access to mRNA under certain stress conditions, such as nutrient deprivation 29 , in most cells and tissues, FTO is detected exclusively in the nucleus 19, 25 . Thus, FTO may have nuclear RNA targets that might account for the diverse phenotypes observed in FTO-deficient mice and humans.
To identify the RNAs that are under control of FTO, we performed miCLIP analysis to map N 6 -methyladenine (6mA) in wild-type and Fto-knockout mouse liver RNA (Extended Data Fig.   1a ). Unlike in previous studies 24, 25 , no poly(A) purification was used, thus allowing all cellular
RNAs to be analyzed. To detect m 6 Am, we searched for RNA species that show increased methylation at the transcription-start nucleotide in the Fto knockout transcriptome compared to wild type. This analysis revealed only a small subset of methylation events that were significantly increased in the Fto knockout transcriptome (Fig. 1a) . Examination of these RNAs showed that they were exclusively small nuclear RNAs (snRNAs), including U1, U4atac, and U5
( Fig. 1a) .
To test whether increased transcription-start nucleotide methylation in the Fto knockout transcriptome is observed in all spliceosomal snRNAs, we next looked specifically at the methylation fold change of Sm-and Lsm-class snRNAs. We observed increased transcriptionstart nucleotide methylation of all Sm-class snRNAs of the major and minor spliceosome ( which is involved in 3'-end processing of histone mRNAs 30 and the small nucleolar RNAs (snoRNAs) U3 and U8 that function in rRNA processing also showed increases transcriptionstart nucleotide methylation in Fto knockout compared to wild-type transcriptome (Extended
Data Figs. 3a-c).
The increase in 6mA reads was seen in all Sm-class snRNAs, but was not seen in the Lsm-class snRNAs U6 and U6atac -the only two spliceosomal snRNAs that are transcribed by RNA polymerase III rather than RNA polymerase II (ref. ). U6 and U6atac do not acquire an m 7 G cap; however, U6 snRNA contains an internal m 6 A at position 43 (ref. 17) . Nevertheless, FTO depletion did not lead to significant upregulation of 6mA reads at this internal position (Figs. 1b, g ). Similarly, U2 snRNA, which contains an m 6 Am at position 36 (ref. 17) , did not show a clear increase of 6mA reads at this internal position (Figs. 1d, g ). Thus, the FTO-regulated sites are specifically localized to the transcription-start nucleotide region of Sm-class snRNAs.
miCLIP does not readily distinguish between mature snRNA and the unprocessed longer snRNA precursors or truncated forms. Therefore, we asked if the increased snRNA methylation upon FTO knockout could be detected in mature snRNAs. To do this, we used 6mA immunoblotting to detect the length of 6mA-immunoreactive snRNAs. In these experiments, we performed 6mA
immunoblot of small RNA (<200 nt) from wild-type and FTO knockout HEK293 cells. We observed bands corresponding to the mature snRNA forms, with significantly increased 6mA-immunoreactivity in FTO knockout cells (Fig. 1h) .
Taken together, these data indicate that all Sm-class snRNAs are substrates for FTO-mediated demethylation during their life cycle.
The first nucleotide of snRNAs is reversibly methylated
The finding that Sm-class snRNA modification is regulated by FTO is surprising, since these snRNAs are not known to contain m 6 Am or m 6 A at the transcription-start nucleotide. Instead, Sm-class snRNAs are thought to only contain 2'-O-methyladenosine (Am) at this position 13 . To biochemically determine the identity of the first nucleotide in snRNAs in wild-type and FTO knockout cells, we used a thin-layer chromatography (TLC)-based approach 23 . In this assay, the 5'-cap is removed from RNA, followed by radiolabeling of the exposed 5' nucleotide with [g-32 P]-ATP. Next, the snRNAs are treated with ribonuclease and the nucleotide hydrolysate is resolved by 2D-TLC. This approach readily resolves whether the first nucleotide is m 6 Am or Am, or any other nucleotide based on its migration pattern 23 .
We first purified the small RNA fraction (<200 nt), since this fraction is highly enriched in snRNAs. Quantification of the first nucleotide of these RNAs from wild-type cells showed a high level of Am, as well as low, but measurable levels of m 6 Am (Fig. 2a) . However, when the small RNA fraction was prepared from FTO knockout HEK293 cells, a substantial increase in the level of m 6 Am at the first nucleotide was readily detected (Fig. 2a) .
To ensure that FTO depletion is affecting snRNA and not some other type of small RNA, we directly measured the first nucleotide in U1 snRNA. To do this, we gel-purified U1 snRNA, a 164 nucleotide-long snRNA that migrates to a well-defined position by PAGE (Figs. 1f, 2b) .
We then used the TLC approach to determine the first nucleotide in the U1 snRNA-enriched fraction. Consistent with previous publications 13 , the first nucleotide in U1 was predominantly Am in wild-type HEK293 cells (Fig. 2b) . However, in U1 snRNA from FTO knockout HEK293 cells, m 6 Am was markedly increased, with levels similar to Am (Fig. 2b) . These data indicate that snRNAs can contain m 6 Am at the first encoded nucleotide.
Among the snRNAs, U2 showed the smallest increase in the miCLIP signal in FTO knockout cells. U2 is difficult to analyze since it contains a constitutive internal m 6 Am, which causes this snRNA to be immunoprecipitated irrespective of the methylation status of its transcription-start nucleotide (Fig. 1d) . Therefore, we also analyzed the 5'-nucleotide of this snRNA by TLC.
Indeed, we observed that FTO knockout resulted in a substantial increase in m 6 Am at the 5'-position of U2 snRNA (Extended Data Fig. 4a ). This indicates that U2 also contains an m 6 Am nucleotide that is regulated by FTO.
To provide an independent measurement to assess whether snRNAs can contain m 6 Am at the first nucleotide, we developed a mass spectrometry-based assay. To ensure that we examined only m 6 Am residues in the context of the cap structure, small RNA was treated with P1 nuclease, resulting in all internal nucleotides being digested to mononucleotides. However, under these conditions, the first nucleotide remains connected to the cap in the form of a "cap-dinucleotide" structure (cap-ppp-Am or cap-ppp-m 6 Am) (Extended Data Fig. 5a ).
Cap-dinucleotides were readily quantified by high-resolution mass spectrometry analysis using positive ion mode detection, since negative ion mode did not allow sensitive detection of capdinucleotides (Extended Data Fig. 5b) . A multiple reaction monitoring protocol was developed based on the fragment ion transitions from distinct dinucleotide precursor species (Extended Data Fig. 5c ). This approach exhibited high sensitivity and linear detection of the first nucleotide within the cap context (Extended Data Fig. 5d ).
Using this approach, we verified that Am was associated with the cap after digestion of small RNA from wild-type HEK293 cells (Fig. 2c, d ). However, m 6 Am was the predominant form in FTO knockout HEK293 cells, with a 6.3-fold enrichment of m 6 Am over Am (Fig. 2c) Fig. 6b, c) .
Together, these data show that the levels of m 2 -snRNAs are regulated and expressed in a cell type-specific manner. (Fig. 2e and Extended Data Fig. 7b ). Similar effects were seen using TLC analysis of U1 snRNA (Extended Data Fig. 7c ).
To confirm that the effect of mutant IDH1 and IDH2 overexpression reflects increased 2-HG levels, we used specific inhibitors for each mutant isoform. Treatment with these inhibitors resulted in marked reduction of m 2 -snRNAs ( Fig. 2e and Extended Data Figs. 7b, c) .
Taken together, these data indicate that m 2 -snRNA levels can be altered by cellular metabolites such as 2-HG. Our finding suggests that m 2 -snRNAs have a role in 2-HG-associated pathogenic conditions. m 6 Am is demethylated prior to cap hypermethylation during snRNA biogenesis
The biogenesis of snRNAs has two nuclear phases [6] [7] [8] . The first nuclear phase comprises transcription and m 7 G capping of precursor snRNAs, which are then exported into the cytoplasm 8 . In the cytoplasm, the snRNAs acquire a TMG cap, and are then subjected to 3' end trimming and nuclear re-import, all of which are dependent on the assembly of Sm proteins [6] [7] [8] 14 .
After the snRNAs are incorporated into small nuclear ribonucleoproteins (snRNPs), the second nuclear phase involves their function in splicing. Since FTO is found exclusively in the nucleus, 3a) . However, no Am formation was detected after FTO treatment of the post-import substrate comprising m 6 Am RNA and a TMG cap (Fig. 3a) . These data suggest that m 2 -snRNAs are not a substrate for FTO after TMG cap formation.
Based on the m 7 G cap-specific demethylation and considering the nuclear localization of FTO, we infer the decision to demethylate m 2 -snRNAs and form m 1 -snRNAs is determined during a specific, early phase of snRNA biogenesis. This phase occurs in the nucleus and the cytoplasm shortly after snRNA transcription but prior to the cytoplasmic formation of the TMG cap and assembly of snRNAs into snRNPs. immunoprecipitated snRNPs from cellular extracts using a small ribonucleoprotein particle protein B (SmB)-specific antibody. This approach has previously been shown to immunoprecipitate assembled snRNPs 36, 37 . We then determined the first nucleotide of snRNAs in cellular snRNPs to determine the levels of m 1 -snRNAs and m 2 -snRNAs. As expected, in control HEK293 cells, predominantly m 1 -snRNAs were detected (Fig. 3b) . However, in FTO knockout HEK293 cells, m 2 -snRNAs were substantially increased (Fig. 3b) In each case, the primary cap structure was the TMG cap attached to m 6 Am (TMG-ppp-m 6 Am) (Fig. 3c, Extended Data Fig. 6a ). This indicates that m 2 -snRNAs are subjected to cap hypermethylation during their biogenesis.
Taken together, these data show that m 2 -snRNAs undergo normal biogenesis, including incorporation into snRNPs and acquisition of the TMG cap structure.
Altered splicing in cells expressing high levels of m 2 -snRNAs
As previously reported 28 , we found that the most pronounced effect of FTO deficiency is increased exon inclusion (Fig. 4a) . To further refine this analysis, we next characterized the included exons for binding sites of known splicing factors in a previously published RNA-Seq analysis using control and FTO knockout HEK293 cells 27 . Here, we observed a significant and specific enrichment for SRSF1, HNRNPH2 and HNRNPK-dependent exons, whereas enrichment of other exons was not detected (Fig. 4b and Extended Data Fig. 8a ). Similar effects were also seen in our independent HEK293T FTO knockdown RNA-Seq dataset (Extended Data Figure 8b ). Together, these data indicate that an increase in m 2 -snRNPs is correlated with specific alternative splicing events, most notably inclusion of exons that would normally be inefficiently spliced into mature mRNA.
Recently, we found that methylation of Am to m 6 Am adjacent to mRNA caps confers substantially elevated stability to mRNA 21 The formation of m 2 -snRNAs and its subsequent demethylation to m 1 -snRNA is a previously unknown step in snRNA biogenesis (Fig. 5) . snRNA biogenesis was extensively studied and involves Sm core assembly, 3' processing, nucleotide modifications at internal sites and formation of the hypermethylated guanosine cap [6] [7] [8] 11, 14, 17 . Our data reveal that spliceosomal snRNA biogenesis also involves a previously unrecognized N 6 -methylation that occurs on the evolutionarily conserved adenosine that is present at the transcription-start nucleotide of all Smclass snRNAs. We find that FTO is a previously unknown snRNA biogenesis enzyme. FTO is involved in snRNA biogenesis by performing a regulated demethylation step of m 2 -snRNAs to m 1 -snRNAs. Thus, our studies reveal that snRNAs exhibit a more complex process of biogenesis than previously known, involving reversible methylation of the extended snRNA cap.
Our finding that FTO is an snRNA biogenesis enzyme helps to explain earlier findings that FTO levels influence alternative splicing. These splicing changes were initially attributed to FTOregulated m 6 A residues around splice-sites, since at the time FTO was thought to target m 6 is not seen at any m 6 Am or any m 6 A site in any mRNA to our knowledge, supporting the idea that the main physiologic targets of FTO are these small nuclear RNAs.
Studies of FTO localization show that FTO co-localizes with nuclear structures linked to premRNA splicing 19 , which is consistent with FTO's action on these RNAs. Since snRNA biogenesis can cause diverse effects on the transcriptome, FTO depletion is expected to have diverse effects on mRNA. However, these effects likely reflect indirect effects of FTO on mRNA through its regulation of snRNA.
Notably, we used direct measurements of the specific methylated and demethylated nucleotides to determine how the stoichiometry of m 6 Am is controlled by FTO in snRNA. Measuring both the methylated and demethylated nucleotide at specific sites in the transcriptome is critical since it provides definitive evidence that FTO can regulate the stoichiometry of methylation. In contrast, immunoprecipitation of methylated RNA, followed by RNA quantification is problematic since the non-methylated nucleotide is not measured. Furthermore, changes in RNA immunoprecipitation can be caused by changes in the RNA levels in the input sample or by other methylated RNAs that compete for immunoprecipitation. Although our data support the idea that FTO -a nuclear-localized enzyme -primarily targets snRNAs, which are also primarily nuclear, it has been suggested that FTO can demethylate m 6 A in cytoplasmic mRNAs. However,
as of yet, no m 6 A site has successfully been shown to be regulated by FTO using SCARLET, a quantitative method for determining m 6 A stoichiometries in mRNA 39 .
After snRNA transcription, the snRNA is methylated to the m 2 form and then demethylated by FTO back to the m 1 form (Fig. 5) . The decision to demethylate the m 2 -snRNA appears to be determined early in snRNA biogenesis and may be important to establish splicing patterns in different cell types or metabolic states. We find that FTO-mediated demethylation of m 2 -snRNAs is inhibited when 2-hydroxyglutarate levels are increased due to expression of a cancerassociated mutant IDH. These data indicate that FTO is a metabolite sensor that connects metabolite abnormalities to snRNA methylation status. FTO was previously shown to be inhibited by metabolites that compete with a-ketoglutarate, including citrate, succinate, fumarate and 2-hydroxyglutarate 31, 32 . Altered levels of these metabolites are seen in diverse cancers [40] [41] [42] [43] , as well as during cellular differentiation 44, 45 . Our studies raise the possibility that metabolite abnormalities may mediate their effects, in part, by inhibiting FTO and increasing the levels of m 2 -snRNAs that can in turn influence specific splicing events.
The presence of m 2 -snRNAs is not restricted to cells that lack FTO or express mutant IDH. We also detected m 2 -snRNAs in mouse embryonic stem cells, TF-1 cells and mouse liver tissue by miCLIP and mass spectrometry. It will be important to determine whether m 2 -snRNAs in these cells accumulate because of FTO inhibition or due to other mechanisms.
At present, the mechanism by which m 6 Am affects the function of snRNAs and snRNPs is not known. m 6 Am may recruit specific "readers," may influence snRNA stability, or could have other effects. Notably, the levels of snRNAs are elevated in FTO-deficient cells. This includes the levels of U6 snRNA, an snRNA that lacks m 6 Am. The U6 snRNP is involved in complexes with other snRNPs that are dynamically assembled and disassembled during splicing. The global elevation in diverse snRNAs suggest that the overall pattern of snRNP turnover is affected by the presence of m 2 -snRNAs. However, a major next step will be to establish a mechanistic explanation for how the presence of m 6 Am influences snRNA/snRNP turnover and how this leads to altered splicing.
Notably, splicing efficiency is directly dependent on the levels of snRNAs and reduced snRNA expression is associated with severe splicing abnormalities 46 . Our data show that FTO deficiency leads to a clear and robust increase of snRNA expression. The increased snRNA expression may influence splicing patterns by specifically promoting the inclusion of exons that are otherwise inefficiently spliced due to rate-limiting levels of snRNPs.
It should be noted that the enhanced splicing activity of m 2 -snRNAs are unlikely to reflect a direct effect of the N 6 -methyl modification on the snRNA:pre-mRNA hybridization steps. These hybrids mostly occur at internal sites in the snRNA. For example, U1 snRNA hybridizes to the 5' splice site using nucleotides 3-7 (ref. 47 ). Therefore, snRNA binding and recognition of target sites in pre-mRNA are unlikely to be promoted by the N 6 -methylation status of the first nucleotide.
Our data provide a new perspective on studies that have explored the physiological effects of respectively. The right panel shows the quantification of 6mA signal in U1 and U2 snRNA relative to the 6mA signal in U6 snRNA. U6 snRNA was used for normalization since it has an internal m 6 A residue that is constitutive and lacks m 6 Am, and therefore is not regulated by FTO.
Notably, we observed strong 6mA immunoreactivity towards U2 snRNA in WT cells and increased methylation in FTO -/-cells did not reach statistical significance. However, U2 snRNA contains a constitutive internal m 6 Am residue (see also Fig. 1d ) that is not demethylated by FTO, which likely masks FTO deficiency-dependent effects (n = 3 independent biological replicates; mean ± s.e.m.; unpaired student's t-test ***P ≤ 0.001). Under basal conditions, m 2 -snRNAs can be converted back to the m 1 isoform by the nuclear RNA demethylase FTO. Similar to m 1 -snRNAs, m 2 -snRNAs are subjected to the normal biogenesis pathway, which involves Sm core assembly, hypermethylation of the m 7 G cap to N 2,2,7 -trimethylguanosine (TMG), reimport into the nucleus, and formation of functional small nuclear ribonucleoprotein complexes (snRNPs) that carry out pre-mRNA splicing.
Notably, in conditions where specific metabolites, such as 2-hydroxyglutarate (2-HG), fumarate and succinate, are increased, FTO activity is inhibited 31, 32 . This results in high levels of m 2 -snRNAs, which leads to inclusion of alternative exons and ultimately determines transcriptome diversity.
Methods miCLIP-based mapping of 6mA at transcription start nucleotides and RNA-Seq analysis
For miCLIP experiments, total RNA was extracted from Fto knockout mouse livers (Fto -/-) and wild-type mouse livers using RNAzol RT (Molecular Research Center, Inc.). miCLIP was carried out as described previously 54 . In miCLIP, 6mA is mapped by immunoprecipitation and crosslinking with a 6mA-binding antibody (see below) 54 . This mapping method detects both Previously published RNA-Seq datasets utilized in the current study 21, 27 were extracted from Gene Expression Omnibus (GEO, NCBI) and, if no processed data was available, the fastq-files were reanalyzed with the pipelines described above.
Cell culture and animals
Flp-In T-REx HEK293 cells (R78007, ThermoFisher Scientific) were maintained in DMEM (ThermoFisher Scientific) with 10% FBS and antibiotics (100 units/ml penicillin and 100 µg/ml of streptomycin) under standard tissue culture conditions. Cells were split using TrypLE™ Express (Life Technologies) according to the manufacturer's instructions.
Control, IDH1
R132H and IDH2 R140Q TF-1 erythroleukemia cells were generated and maintained as previously described 34 . Intracellular 2-hydroxyglutarate concentrations were determined as previously described 34 . All experiments involving TF-1 cells were carried out between passage 5-10. To inhibit production of neomorphic 2-hydroxyglutarate, IDH1 R132H cells or IDH2 R140Q cells were treated for 7 days with 1 µM AGI-5027 (SML1298, Sigma-Aldrich) or AGI-6780 (SML0895, Sigma-Aldrich), respectively.
Naive mouse embryonic stem cells (mESCs) were maintained in Knockout DMEM (ThermoFisher Scientific) with 15% FBS, antibiotics (100 units/ml penicillin and 100 µg/ml of streptomycin), 2mM L-glutamine, 50 µM b-mercaptoethanol (ThermoFisher Scientific), nonessential amino acids (ThermoFisher Scientific), recombinant mouse LIF (EMD Millipore), GSK3 inhibitor (04000402, Stemgent) and MEK1 inhibitor (04000602, Stemgent) under standard tissue culture conditions. To induce differentiation, naive mESCs were deprived of LIF, GSK3 inhibitor and MEK1 inhibitor for 7 days. Mycoplasma contamination in all cell lines used in this study was routinely tested by PCR.
Fto knockout mice were bred as previously described 24 . Only male mice at the age of 12-16 weeks were used for the experiments. All experiments involving mice were approved by the Institutional Animal Care and Use Committee at Weill Cornell Medicine.
Antibodies
Antibodies used were as follows. For western blot analysis mouse a-FTO (ab92821, Abcam) and mouse a-ACTB (A2228, Sigma) were used. For 6mA-immunoprecipitation/miCLIP, rabbit a6mA (202-003, Synaptic Systems) was used. For SmB-IP, a previously described mouse a-SmB antibody (clone 18F6) 59 was used. For 6mA immunoblotting, a rabbit a-6mA antibody (ab190886, Abcam) was used. After UV crosslinking at 120,000 µJ/cm2 in a Stratalinker UV crosslinker (Stratagene), the membrane was blocked with 1% dry milk powder in PBS-T for 1 h at room temperature and then incubated with the a-6mA (1:500) overnight at 4°C. After washing with PBS-T, membranes
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were incubated with a-rabbit HRP-conjugated secondary antibody diluted 1:2500 with 1% dry milk powder in PBS-T for 1 h at room temperature. The membrane was visualized by Pierce ECL Western Blotting Substrate (ThermoFisher Scientific) and a Bio-Rad Gel Doc XR system.
The quantification of the band intensity was analyzed using Bio-Rad Image Lab software.
Determination of relative m 6 Am and Am levels in small RNAs by thin layer chromatography
The m 6 Am/Am ratio in small RNAs was determined as previously described 21 , with some modifications. The small RNA fraction (< 200 nucleotides) was isolated from total RNA using RNAzol RT (Molecular Research Center, Inc.).
For the analysis of individual U-RNAs, the small RNA fraction was separated on 6% TBE-Urea gels. Small RNAs were stained with SYBR Gold (ThermoFisher Scientific) and the respective bands (~160 nucleotide for U1 snRNA, and ~180 nucleotides for U2 snRNA) were excised and for 3h at 37°C.
The nucleotide mixture was subsequently dried using an Eppendorf Vacufuge and reconstituted with 3 µL ddH 2 O. 1 µl of the released 5' monophosphates from this digest were then analyzed by 2D-TLC on glass-backed PEI-cellulose plates (MerckMillipore) as described previously 21 .
Developed TLC plates were imaged as described previously 21 .
Protein expression and purification
Full-length, recombinant human FTO was expressed and purified as previously described 21 .
Notably, to avoid any unspecific activity, it is advisable to express full-length FTO since the positively charged N-terminus of FTO may interact with the negatively charged m 7 G-ppp-cap of RNA.
Recombinant human TGS1 (hTGS1) was expressed and purified as previously described 60, 61 .
Briefly, E. coli Tuner cells transformed with pRSET-A-hTGS1 618-853 were grown at 37 °C in 2YT medium until OD 600 of 0.6 and induced with 0.2 mM IPTG. After overnight expression at 18°C, cells were lysed and the protein was purified via Ni-NTA (binding buffer: 50 mM Tris, pH 8, 1 M NaCl, 10 % glycerol; elution buffer: additional 500 mM imidazole) followed by gel filtration (Superdex 75, running buffer: 50 mM Tris, pH 7.5, 200 mM NaCl, 10 % glycerol) to obtain RNase-free protein that was concentrated to ~1.5 mg/mL (MW: 27 kDa), flash frozen and stored at -20°C.
Synthesis and characterization of synthetic oligonucleotides
Synthetic RNA oligonucleotides were chemically assembled as previously described 21 Gppp-capped ONs were purified by IEX-HPLC and they were characterized by mass spectrometry MALDI-TOF as previously described 21 .
Measurement of FTO activity
In vitro demethylation measurements were performed as described previously 21 . Briefly, 
Sample preparation for HPLC analysis
After treatment with recombinant, full-length human FTO, oligonucleotides were decapped with 25 units of RppH (NEB) in ThermoPol buffer for 3 h at 37°C. RNA was subsequently digested to single nucleotides with 200 units S1 nuclease (Takara) for 2h at 37°C. 5' phosphates were removed with 5 units rSAP (NEB) for 1h at 37°C. Before loading the samples onto the HPLC column, proteins were removed by size exclusion chromatography with a 10-kDa cut-off filter (VWR).
HPLC analysis of demethylation activity
The HPLC analysis of nucleosides was performed on an Agilent 1100 system (Agilent 
Sample preparation for mass spectrometry
In addition to their modified starting nucleotides (m 6 Am or Am), most snRNAs contain additional internal 2'-O-methylated adenosine (Am) residues 13 . Due to possible shearing of the RNA during the extraction process, these internal Am residues could be exposed and lead to unspecific background signal in thin layer chromatography. To eliminate this possible source of error, we sought to develop and independent method to measure the precise ratio of m 6 Am and Am caps in snRNA. We therefore developed a protocol to liberate intact cap-dinucleotides from the snRNA backbone and detect these cap-dinucleotides by LC-MS/MS.
To do this, cellular small RNA (0.1-1 µg) was digested with P1 nuclease (0. Corporation, NJ), at a column compartment temperature of 40°C. The samples were maintained at 4°C and the injection volume was 2 µL. The gradient-chromatography previously described by
Chen et al. 62 was optimized to achieve chromatographic separation of TMG-ppp-m 6 Am and TMG-ppp-Am. The aqueous mobile phase (A) was 50% isopropanol with 0.025% acetic acid, the organic mobile phase (B) was 90% acetonitrile containing 5 mM ammonium acetate. To eliminate the interference of metal ions on the chromatographic peak integrity and ESI ionization, 
Immunoprecipitation of spliceosomal complexes
SmB immunoprecipitations were performed as described previously 36, 37 . Briefly, extracts were prepared in ice cold RSB-100 buffer (100 mM NaCl, 10 mM Tris-HCl pH 7.4, 2.5 mM MgCl 2 ) containing 0.1% NP40, protease, phosphatase and RNAse inhibitors, by passing five times through a 26-gauge needle followed by 3 x 5 seconds bursts of sonication on ice and centrifugation at 20,000 x g for 15 minutes at 4°C. Extract supernatant was quantified by BCA Assays (ThermoFisher Scientific). 
Alternative splicing analysis
For alternative splicing analysis, paired reads were aligned to the human transcriptome (hg19) or mouse transcriptome (mm10) using STAR 56 (v020201). Biological replicates were then merged and indexed using samtools (v1.5). The module exon_utils from the MISO package 63 was first used to extract the constitutive exons from the transcriptome annotation (iGenomes, UCSC build hg19). The resulting annotations were then used in conjunction with the pe_utils module (MISO)
to estimate fragment length distribution. The MISO package was then used to quantify percent spliced-in values (PSI) for each splicing event annotated for hg19 (pre-built MISO annotations).
For this analysis, we used skipped exons (SE) as well as alternatively spliced first and last exons (A5SS and A3SS). We then used MISO to compare changes in splicing events, which reports the change in PSI values as well as the associated Bayes factor. For motif analysis, we extracted the included exons along with 250nt flanking sequences. We then used FIRE 53 , in non-discovery mode, to ask whether the presence or absence of known splicing regulator binding sites 64 were significantly associated with changes in PSI values. In addition to enrichment profiles among the down-or up-regulated exons, FIRE also provides the mutual information (MI) values and their associated z-scores and robustness scores.
Classification of mRNAs based on the first nucleotide
In experiments where we compared snRNAs to m 6 Am, Am, Cm, Gm, and Um-initiated mRNAs, we classified the mRNAs based on the nucleotide at the annotated transcription start site (TSS).
Annotated TSS were extracted from UCSC table browser. A complete list of transcripts with their respective annotated transcription start site is found in the Supplementary Information Table S1 .
Code availability
All custom code used in this study can be obtained upon request from the lead author (S.R.J:
srj2003@med.cornell.edu).
Statistics and software
P-values were calculated with a two-tailed unpaired Student's t-test or, for the comparison of more than two groups, with a one-or two-way ANOVA followed by Tukey's post-test. P-values of 0.05 or less were considered significant. Sm-snRNA; adj. P-value < 0.05 Figure 5 Nucleus Cytosol Sm-class snRNA P P P P P P P P P P P P P P P P P P
